刚刚，利好来了！创新药大消息

Core Viewpoint - The Chongqing Municipal Government has issued measures to support the high-quality development of innovative drugs, aiming to enhance the local pharmaceutical industry by increasing the number of approved innovative drugs and fostering a comprehensive innovation ecosystem by 2027 [1][8]. Group 1: Overall Goals - By 2027, Chongqing aims to approve 1 to 3 innovative drugs annually, with a total of 10 innovative drugs, 3 industrial innovation complexes, 3 high-level innovation platforms, and 3 innovative drug industry clusters [1][8]. Group 2: Encouragement of R&D - Financial support will be provided for innovative drug projects at various clinical trial stages, with funding up to 20% of total R&D costs, capped at 2 million yuan for preclinical and phase I trials, 3 million yuan for phase II trials, and 10 million yuan for phase III trials [2][9]. - Support for the development of traditional Chinese medicine (TCM) will include a 100,000 yuan reward for each TCM product that completes registration and achieves sales [4][12]. Group 3: Industrialization Support - A reward of 10 million yuan will be given for each approved innovative drug, 5 million yuan for improved new drugs and biosimilars, and 1 million yuan for classic TCM products [2][12]. - Financial support for advanced manufacturing platforms will be capped at 1 million yuan, covering up to 20% of fixed asset investments [2][12]. Group 4: Clinical Research and Trial Enhancements - The establishment of a clinical trial responsibility risk compensation mechanism will encourage insurance companies to develop relevant insurance products, with subsidies for insured companies covering 50% of premiums [3][11]. - The measures will streamline the ethical review process for clinical trials, aiming to reduce the overall time for trial initiation to within 25 weeks [11][12]. Group 5: Market Access and Insurance Support - The measures will facilitate faster market access for innovative drugs, with a commitment to complete the listing process within 15 working days for products on the application list [12][13]. - The government will enhance communication channels between insurance departments and innovative drug companies to support the inclusion of innovative drugs in medical insurance [13][14]. Group 6: Talent and Ecosystem Development - The initiative emphasizes the importance of talent cultivation and attracting skilled professionals in the biopharmaceutical sector, aiming to build a robust ecosystem for innovative drug development [14][15]. - The establishment of specialized industrial parks and innovation platforms is planned to foster collaboration among enterprises, research institutions, and universities [14][15].